Brought to you by 
Merus raises €21.7mm through its Series B round; closes at €47.6mm
04 Oct 2013
Executive Summary
Merus (cancer, inflammation, and infectious disease therapeutics) has raised €21.7mm ($30.7mm) through its Series B venture round. New investors Novartis Option Fund, Pfizer Venture Investments, Bay City Capital, and Life Science Partners co-led the financing and were joined by current shareholder Aglaia Oncology Fund.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merus raises €21.7mm through its Series B round; closes at €47.6mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice